AnewPharma Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2013
NCT01863485
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

AnewPharma

Active Ingredients

Drugs in Phase 3 Trials (2)

cm-082 (4 trials)

everolimus (zortress) (2 trials)

Drugs in Phase 2 Trials (2)

cm082 (10 trials)

triprizumab (3 trials)

Drugs in Phase 1 Trials (1)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 3)

Choroidal Neovascularization (Phase 1)

Lung Neoplasms (Phase 2)

Macular Degeneration (Phase 2)

Melanoma (Phase 2)

Myopia (Phase 1)

Neoplasms (Phase 1)

Neovascularization, Pathologic (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 5